Beobachtungsplan, NIS 348: Pertuzumab in First Line Treatment of HER2-positive metastatic breast Cancer patients: A cohort study of patients treated either with docetaxel and Trastuzumab or docetaxel, trastuzumab and pertuzumab

Datei

• Artikel "Beobachtungsplan, NIS 348: Pertuzumab in First Line Treatment of HER2-positive metastatic breast Cancer patients: A cohort study of patients treated either with docetaxel and Trastuzumab or docetaxel, trastuzumab and pertuzumab"Herunterladen(PDF, 1MB, Datei ist nicht barrierefrei)